Cargando…
Therapeutic potential of GSK-J4, a histone demethylase KDM6B/JMJD3 inhibitor, for acute myeloid leukemia
PURPOSE: Acute myeloid leukemia (AML) is a heterogeneous disease with poor outcomes. Despite increased evidence shows that dysregulation of histone modification contributes to AML, specific drugs targeting key histone modulators are not applied in the clinical treatment of AML. Here, we investigated...
Autores principales: | Li, Yunan, Zhang, Mingying, Sheng, Mengyao, Zhang, Peng, Chen, Zizhen, Xing, Wen, Bai, Jie, Cheng, Tao, Yang, Feng-Chun, Zhou, Yuan |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer Berlin Heidelberg
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5948279/ https://www.ncbi.nlm.nih.gov/pubmed/29594337 http://dx.doi.org/10.1007/s00432-018-2631-7 |
Ejemplares similares
-
The pharmacological role of histone demethylase JMJD3 inhibitor GSK-J4 on glioma cells
por: Sui, Aixia, et al.
Publicado: (2017) -
Heme promotes transcriptional and demethylase activities of Gis1, a member of the histone demethylase JMJD2/KDM4 family
por: Lal, Sneha, et al.
Publicado: (2018) -
Jmjd2/Kdm4 demethylases are required for expression of Il3ra and survival of acute myeloid leukemia cells
por: Agger, Karl, et al.
Publicado: (2016) -
The JMJD3 histone demethylase inhibitor GSK-J1 ameliorates lipopolysaccharide-induced inflammation in a mastitis model
por: Wang, Jing-Jing, et al.
Publicado: (2022) -
Regulation of the JMJD3 (KDM6B) histone demethylase in glioblastoma stem cells by STAT3
por: Sherry-Lynes, Maureen M., et al.
Publicado: (2017)